• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Trombetta Giandomenico was granted 112,356 shares, increasing direct ownership by 1% to 10,418,382 units (SEC Form 4)

    8/30/24 5:03:46 PM ET
    $MLSS
    Industrial Specialties
    Health Care
    Get the next $MLSS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Trombetta Giandomenico

    (Last) (First) (Middle)
    C/O MILESTONE SCIENTIFIC INC.
    425 EAGLE ROCK AVENUE, SUITE 403

    (Street)
    ROSELAND NJ 07068

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    MILESTONE SCIENTIFIC INC. [ MLSS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    08/28/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, Par Value $0.001 08/28/2024 A 112,356(1) A $0.89 10,418,382 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents the annual fee paid to non-employee directors of $100,000, payable in restricted shares of the Company's common stock one-fourth vesting upon the grant and the balance vesting in equal tranches over the next three quarters, October 1, 2024, January 1, 2025, and April 1, 2025
    /s/ Giandomenico Trombetta 08/30/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MLSS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MLSS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MLSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mcgeehan Michael sold $15,532 worth of shares (20,000 units at $0.78), decreasing direct ownership by 3% to 575,273 units (SEC Form 4)

      4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)

      12/20/24 4:00:59 PM ET
      $MLSS
      Industrial Specialties
      Health Care
    • Director Osser Leonard sold $100,425 worth of shares (107,984 units at $0.93), decreasing direct ownership by 2% to 4,606,882 units (SEC Form 4)

      4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)

      10/23/24 4:55:21 PM ET
      $MLSS
      Industrial Specialties
      Health Care
    • Director Mcgeehan Michael sold $209 worth of shares (209 units at $1.00), decreasing direct ownership by 0.04% to 595,273 units (SEC Form 4)

      4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)

      9/27/24 9:12:50 AM ET
      $MLSS
      Industrial Specialties
      Health Care

    $MLSS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Milestone Scientific Reports Revenue of $2.2 Million and Provides Business Update for the First Quarter of 2025

      ROSELAND, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and reported financial results for the first quarter ended March 31, 2025. Neal Goldman, Chairman and Interim Chief Executive Officer of Milestone Scientific, commented, "We are encouraged by the growing momentum in our medical segment, where first quarter results reflect increased traction for the CompuFlo® Epidural System. During the quarter, we were pleased to see new practices integrating CompuFlo into their workflows. These adoptions reflect both the clinical

      5/15/25 4:15:00 PM ET
      $MLSS
      Industrial Specialties
      Health Care
    • Milestone Scientific Reports Year-End 2024 Financial Results and Reports Strong Outlook for 2025

      Reports expansion of CompuFlo® Epidural System across additional pain management clinics and ambulatory surgery centers following Medicare price assignment in multiple U.S. states ROSELAND, N.J., April 15, 2025 (GLOBE NEWSWIRE) --  Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the year ended December 31, 2024. Neal Goldman, Chairman and Interim Chief Executive Officer of Milestone Scientific, stated, "While 2024 was a year of transition for Milestone Scientific, we laid the foundation for a strong rebound in 2025. We foc

      4/15/25 4:10:00 PM ET
      $MLSS
      Industrial Specialties
      Health Care
    • Milestone Scientific Expands CompuFlo® Epidural System Footprint with InfiniSurg, LLC in New Jersey

      ROSELAND, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that InfiniSurg, LLC, a premier ambulatory surgery center based in New Jersey, has incorporated the CompuFlo® Epidural System into its clinical practice. The device will be utilized by Roman Kosiborod, DO, a highly experienced anesthesiologist and pain management physician. This order was received through Milestone's distributor, Axial Biologics. Dr. Kosiborod brings over two decades of expertise in interventional pain management and ambulatory anesthesia. He is the Managing Dir

      4/1/25 8:30:00 AM ET
      $MLSS
      Industrial Specialties
      Health Care

    $MLSS
    Financials

    Live finance-specific insights

    See more
    • Milestone Scientific Achieves 22% Increase in Revenue for the Third Quarter of 2024

      Reports 57% increase in international dental sales for the third quarter of 2024 Advances commercial rollout of CompuFlo® Epidural System across additional pain management clinics following Medicare price assignment in multiple U.S. states ROSELAND, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today reported financial results for the third quarter ended September 30, 2024. Arjan Haverhals, CEO of Milestone Scientific, commented, "We are pleased to report a 22% year-over-year increase in total revenue, reaching $2.5 million for t

      11/14/24 4:30:00 PM ET
      $MLSS
      Industrial Specialties
      Health Care
    • Milestone Scientific Schedules Third Quarter 2024 Financial Results and Business Update Conference Call

      ROSELAND, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Friday, November 15th, 2024, to discuss the company's financial results for the third quarter ended September 30, 2024, as well as the company's corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 169295. A webcast and replay of the call may be acc

      11/12/24 8:30:00 AM ET
      $MLSS
      Industrial Specialties
      Health Care
    • Milestone Scientific Provides Business Update and Reports Financial Results for the Second Quarter of 2024

      Secured Medicare price assignment for the CompuFlo® Epidural System in multiple U.S. states Gross margin for the second quarter of 2024 increased to 76.1% from 65.0% for the same period last year driven by an increase in U.S. e-commerce sales ROSELAND, N.J., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and reported financial results for the second quarter ended June 30, 2024. Arjan Haverhals, CEO and President of Milestone Scientific, commented, "We are successfully advancing our reimbursement strategy for the CompuFlo®

      8/15/24 7:00:00 AM ET
      $MLSS
      Industrial Specialties
      Health Care

    $MLSS
    Leadership Updates

    Live Leadership Updates

    See more
    • Milestone Scientific Announces CEO Transition, with Chairman Neal Goldman Serving as Interim CEO

      ROSELAND, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that its Chief Executive Officer Arjan Haverhals will retire from his role as an officer of the company on December 31, 2024. Upon his retirement, Mr. Haverhals will continue to serve as a director on the Board and will provide consulting services to ensure continuity and support through the leadership transition. Mr. Haverhals' retirement, following a distinguished career of over 30 years in the medical device and pharmaceutical industries, reflects his desire to spend more ti

      11/14/24 4:00:00 PM ET
      $CTHR
      $MLSS
      Consumer Specialties
      Consumer Discretionary
      Industrial Specialties
      Health Care
    • Milestone Scientific Appoints Pain Management Industry Veteran Dr. Didier Demesmin to its Board of Directors

      ROSELAND, N.J., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Dr. Didier Demesmin, MD, MBA, to the Board of Directors. Dr. Demesmin is an interventional pain medicine physician who is double board-certified in both anesthesiology and pain medicine. He is the founder of University Pain and Spine center, a well-respected interventional pain management and spine surgery clinic that operates 7 offices across New Jersey and New York. He is also the founder of STEMMEE Surgery Center, an ambulatory surgery center providing st

      9/12/23 11:00:00 AM ET
      $MLSS
      Industrial Specialties
      Health Care
    • Milestone Scientific Announces Distribution Agreement with Leading European Dental Distributor & Manufacturer Sweden & Martina

      ROSELAND, N.J., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provides painless and precise injections, today announced it has entered into a distribution agreement with Sweden & Martina, a leading European dental distributor and manufacturer. Under the agreement, Sweden & Martina has been awarded the exclusive rights to market Milestone's STA Single Tooth Anesthesia System® (STA) in the new markets of Spain, Portugal and France. In addition, Sweden & Martina will replace the Company's current distributor in Italy and become its exclusive STA distributor in this market. Founded in 1972, Sweden &

      1/12/23 8:30:00 AM ET
      $MLSS
      Industrial Specialties
      Health Care

    $MLSS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Milestone Scientific Inc.

      10-Q - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)

      5/15/25 4:01:13 PM ET
      $MLSS
      Industrial Specialties
      Health Care
    • Milestone Scientific Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)

      4/22/25 4:10:54 PM ET
      $MLSS
      Industrial Specialties
      Health Care
    • SEC Form 10-K filed by Milestone Scientific Inc.

      10-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)

      4/15/25 4:01:07 PM ET
      $MLSS
      Industrial Specialties
      Health Care